Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06215911 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Reduced Ejection Fraction (Cycle-1-REF)
A Phase 2 study, sponsored by Cardurion Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 557
- Enrollment target
NCT06215911: Completed Phase 2 study, sponsored by Cardurion Pharmaceuticals.
NCT06215911 is a Phase 2 study that has completed, run by Cardurion Pharmaceuticals. The registered enrollment target is 557 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (319% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06215911, a Phase 2 study, has completed, sponsored by Cardurion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 557 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of tovinontrine compared to placebo to lower NT-proBNP in patients with chronic heart failure with reduced ejection fraction.
Primary Outcome
The percent change in plasma NT-proBNP from Baseline to Week 12.
Interventions
- DRUG Placebo
- DRUG Tovinontrine (CRD-750)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 557 participants |
| Start Date | 2024-02-13 |
| Est. Completion | 2025-10-10 |
| Phase | Phase 2 |
What the finished NCT06215911 record still lists
NCT06215911 is an interventional study that assigns participants to a tested intervention. The registered 557 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (319% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06215911 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06215911 about?
NCT06215911 is a clinical study titled "A Study to Assess Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Reduced Ejection Fraction (Cycle-1-REF)". The purpose of this study is to evaluate the safety and effectiveness of tovinontrine compared to placebo to lower NT-proBNP in patients with chronic heart failure with reduced ejection fraction.
What is the current status of trial NCT06215911?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 557 participants. The study started on 2024-02-13. Estimated completion is 2025-10-10.
What interventions are being tested in trial NCT06215911?
The interventions under investigation include: Placebo (DRUG), Tovinontrine (CRD-750) (DRUG).
Who is sponsoring clinical trial NCT06215911?
This trial is sponsored by Cardurion Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06215911's enrollment target sits among peer trials
557 60th of 2000 higher than 1,941 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05708885 · 557 participants · NA
Striated Esophageal Motor Function Modulation in Health and Disease
- NCT07173751 · 558 participants · Phase 3
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
- NCT06074588 · 556 participants · Phase 3
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
- NCT06693622 · 556 participants
Patient Preferences for Barrett's Esophagus and Esophageal Cancer Screening Tests
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI